|
1
|
Clarke CJ and Holyoake TL: Preclinical
approaches in chronic myeloid leukemia: From cells to systems. Exp
Hematol. 47:13–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng Z, Yang N, Liang W, Yan X, Li L and
Pan L: Effect of phosphatase and tensin homology deleted on
chromosome 10 (PTEN) gene transfection on reversal of multidrug
resistance in K562/ADM cells. Leuk Lymphoma. 53:1383–1389. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yin J and Zhang J: Multidrug
resistance-associated protein 1 (MRP1/ABCC1) polymorphism: From
discovery to clinical application. Zhong Nan Da Xue Xue Bao Yi Xue
Ban. 36:927–938. 2011.PubMed/NCBI
|
|
4
|
Reznicek J, Ceckova M, Ptackova Z,
Martinec O, Tupova L, Cerveny L and Staud F: MDR1 and BCRP
transporter-mediated drug-drug interaction between rilpivirine and
abacavir and effect on intestinal absorption. Antimicrob Agents
Chemother. 61:e00837–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen JR, Jia XH, Wang H, Yi YJ, Wang JY
and Li YJ: Timosaponin A-III reverses multi-drug resistance in
human chronic myelogenous leukemia K562/ADM cells via
downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt
signaling pathway. Int J Oncol. 48:2063–2070. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang KL, O'Connor C, Veiga JP, McCarthy
TV and Keeshan K: TRIB2 regulates normal and stress-induced
thymocyte proliferation. Cell Discov. 2:150502016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gilby DC, Sung HY, Winship PR, Goodeve AC,
Reilly JT and Kiss-Toth E: Tribbles-1 and −2 are tumour
suppressors, down-regulated in human acute myeloid leukaemia.
Immunol Lett. 130:115–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yokoyama T and Nakamura T: Tribbles in
disease: Signaling pathways important for cellular function and
neoplastic transformation. Cancer Sci. 102:1115–1122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hannon MM, Lohan F, Erbilgin Y, Sayitoglu
M, O'Hagan K, Mills K, Ozbek U and Keeshan K: Elevated TRIB2 with
NOTCH1 activation in paediatric/adult T-ALL. Br J Haematol.
158:1–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hill R, Madureira PA, Ferreira B, Baptista
I, Machado S, Colaco L, Santos M, Liu NS, Dopazo A, Ugurel S, et
al: TRIB2 confers resistance to anti-cancer therapy by activating
the serine/threonine protein kinase AKT. Nat Commun. 8:146872017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen T, Wang C, Liu Q, Meng Q, Sun H, Huo
X, Sun P, Peng J, Liu Z, Yang X and Liu K: Dasatinib reverses the
multidrug resistance of breast cancer MCF7 cells to doxorubicin by
downregulating P-gp expression via inhibiting the activation of ERK
signaling pathway. Cancer Biol Ther. 16:106–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan WQ, Zhang RR, Wang J, Ma Y, Li WX,
Jiang RW and Cai SH: Asclepiasterol, a novel C21 steroidal
glycoside derived from asclepias curassavica, reverses tumor
multidrug resistance by down-regulating P-glycoprotein expression.
Oncotarget. 7:31466–31483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheng Y, You Y and Chen Y: Dual-targeting
hybrid peptide-conjugated doxorubicin for drug resistance reversal
in breast cancer. Int J Pharm. 512:1–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jacobs RW, Awan FT, Leslie LA, Usmani SZ
and Ghosh N: The shrinking role of chemotherapy in the treatment of
chronic lymphocytic leukemia. Expert Rev Hematol. 9:1177–1187.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li N, Jia X, Wang J, Li Y and Xie S:
Knockdown of homeobox A5 by small hairpin RNA inhibits
proliferation and enhances cytarabine chemosensitivity of acute
myeloid leukemia cells. Mol Med Rep. 12:6861–6866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Jia XH, Chen JR, Yi YJ, Wang JY,
Li YJ and XIE SY: HOXB4 knockdown reverses multidrug resistance of
human myelogenous leukemia K562/ADM cells by downregulating P-gp,
MRP1 and BCRP expression via PI3K/Akt signaling pathway. Int J
Oncol. 49:2529–2537. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yi YJ, Jia XH, Wang JY, Li YJ, Wang H and
Xie SY: Knockdown of HOXA10 reverses the multidrug resistance of
human chronic mylogenous leukemia K562/ADM cells by downregulating
P-gp and MRP-1. Int J Mol Med. 37:1405–1411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao L, Shan Y, Liu B, Li Y and Jia L:
Functional screen analysis reveals miR-3142 as central regulator in
chemoresistance and proliferation through activation of the
PTEN-AKT pathway in CML. Cell Death Dis. 8:e28302017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu W, He J, Yang Y, Guo Q and Gao F:
Upregulating miR-146a by physcion reverses multidrug resistance in
human chronic myelogenous leukemia K562/ADM cells. Am J Cancer Res.
6:2547–2560. 2016.PubMed/NCBI
|
|
20
|
Zhou H, Li Y, Liu B, Shan Y, Li Y, Zhao L,
Su Z and Jia L: Downregulation of miR-224 and let-7i contribute to
cell survival and chemoresistance in chronic myeloid leukemia cells
by regulating ST3GAL IV expression. Gene. 626:106–118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Keeshan K, He Y, Wouters BJ, Shestova O,
Xu L, Sai H, Rodriguez CG, Maillard L, Tobias JW, Valk P, et al:
Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous
leukemia. Cancer Cell. 10:401–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang S and Liu G: Targeting the
Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett.
13:1041–1047. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo Y, Ding Y, Zhang T and An H: Sinapine
reverses multi-drug resistance in MCF-7/dox cancer cells by
downregulating FGFR4/FRS2alpha-ERK1/2 pathway-mediated NF-kappaB
activation. Phytomedicine. 23:267–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buonato JM and Lazzara MJ: ERK1/2 blockade
prevents epithelial-mesenchymal transition in lung cancer cells and
promotes their sensitivity to EGFR inhibition. Cancer Res.
74:309–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao YY, Yu L, Liu BL, He XJ and Zhang BY:
Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic
trioxide-induced reduction in drug resistance towards doxorubicin
in gastric cancer cell lines. Mol Med Rep. 12:7335–7343. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan DP, Zhang YM, Hu XC, Li JJ and Zhang
W: Activation of AKT/ERK confers non-small cell lung cancer cells
resistance to vinorelbine. Int J Clin Exp Pathol. 7:134–143.
2013.PubMed/NCBI
|
|
28
|
Ochi N, Takigawa N, Harada D, Yasugi M,
Ichihara E, Hotta K, Tabata M, Tanimoto M and Kiura K: Src mediates
ERK reactivation in gefitinib resistance in non-small cell lung
cancer. Exp Cell Res. 322:168–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Droebner K, Pleschka S, Ludwig S and Planz
O: Antiviral activity of the MEK-inhibitor U0126 against pandemic
H1N1v and highly pathogenic avian influenza virus in vitro and in
vivo. Antiviral Res. 92:195–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shukla V, Coumoul X, Wang RH, Kim HS and
Deng CX: RNA interference and inhibition of MEK-ERK signaling
prevent abnormal skeletal phenotypes in a mouse model of
craniosynostosis. Nat Genet. 39:1145–1150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tong Y, Huang H and Pan H: Inhibition of
MEK/ERK activation attenuates autophagy and potentiates
pemetrexed-induced activity against HepG2 hepatocellular carcinoma
cells. Biochem Biophys Res Commun. 456:86–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gu FM, Li QL, Gao Q, Jiang JH, Huang XY,
Pan JF, Fan J and Zhou J: Sorafenib inhibits growth and metastasis
of hepatocellular carcinoma by blocking STAT3. World J
Gastroenterol. 17:3922–3932. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gleixner KV, Schneeweiss M, Eisenwort G,
Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G,
Konopleva M, et al: Combined targeting of STAT3 and STAT5: A novel
approach to overcome drug resistance in chronic myeloid leukemia.
Haematologica. 102:1519–1529. 2017. View Article : Google Scholar : PubMed/NCBI
|
